Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vivek Subbiah

Showing results (471-480 of 487) with videos related to

Pageof 49
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2017
Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced CancerFilip Janku, Shile Zhang, Jill Waters, et al.
Cancer Discovery|June 4, 2023
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance MutationsVivek Subbiah, Vaibhav Sahai, Dejan Maglic, et al.
Cell Reports. Medicine|May 21, 2026
Biomarker study of pembrolizumab in patients with advanced rare cancersAung Naing, Xiqi Li, Qi Wang, et al.
Lung Cancer (Amsterdam, Netherlands)|October 23, 2020
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatmentVivek Subbiah, Luis Paz-Ares, Benjamin Besse, et al.
Cancer Immunology Research|October 30, 2019
Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal ResponsesJames W Welsh, Chad Tang, Patricia de Groot, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 29, 2020
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven MalignanciesBenjamin J Solomon, Lavinia Tan, Jessica J Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2026
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced <i>RET</i> Fusion-Positive Non-Small Cell Lung CancerBenjamin Besse, Vivek Subbiah, Giuseppe Curigliano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2023
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)Roberto Carmagnani Pestana, Justin T Moyers, Jason Roszik, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 9, 2025
Molecular Tumor Boards: A Consensus Statement From the International Association for the Study of Lung CancerMihaela Aldea, Julia K Rotow, Maria Arcila, et al.
Cancer Research Communications|November 18, 2025
Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor PatientsVivek Subbiah, Peter P Yu, Rangaprasad Sarangarajan, et al.
Pageof 49

Showing results (471-480 of 487) with videos related to

Sort By:
Pageof 49
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2017
Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced CancerFilip Janku, Shile Zhang, Jill Waters, et al.
Cancer Discovery|June 4, 2023
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance MutationsVivek Subbiah, Vaibhav Sahai, Dejan Maglic, et al.
Cell Reports. Medicine|May 21, 2026
Biomarker study of pembrolizumab in patients with advanced rare cancersAung Naing, Xiqi Li, Qi Wang, et al.
Lung Cancer (Amsterdam, Netherlands)|October 23, 2020
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatmentVivek Subbiah, Luis Paz-Ares, Benjamin Besse, et al.
Cancer Immunology Research|October 30, 2019
Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal ResponsesJames W Welsh, Chad Tang, Patricia de Groot, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 29, 2020
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven MalignanciesBenjamin J Solomon, Lavinia Tan, Jessica J Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2026
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced <i>RET</i> Fusion-Positive Non-Small Cell Lung CancerBenjamin Besse, Vivek Subbiah, Giuseppe Curigliano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2023
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)Roberto Carmagnani Pestana, Justin T Moyers, Jason Roszik, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 9, 2025
Molecular Tumor Boards: A Consensus Statement From the International Association for the Study of Lung CancerMihaela Aldea, Julia K Rotow, Maria Arcila, et al.
Cancer Research Communications|November 18, 2025
Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor PatientsVivek Subbiah, Peter P Yu, Rangaprasad Sarangarajan, et al.
Pageof 49